With reference to the announcements on September 13. and September 21. regarding Arctic Bioscience Capital Markets Update.
On Wednesday 21. September Arctic Bioscience held a Capital Markets Update at Flyt Conference Center in Oslo. A recording of this event has now been made available.
Please see the following link for the recording:
The webcast is also available on the company’s Investor Relations web page.
For more information, please contact:
Jone R. Slinning
CFO of Arctic Bioscience
Phone: +47 948 75 469
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds.
The company is developing HRO350 – a novel oral drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. This is a large patient group in need of new effective medicines with beneficial safety profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in developing marine oils and experience from global pharmaceutical companies.